Barclays Cuts Progyny (NASDAQ:PGNY) Price Target to $23.00

Progyny (NASDAQ:PGNY) had its target price trimmed by Barclays from $29.00 to $23.00 in a report released on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other equities research analysts also recently issued reports on PGNY. Canaccord Genuity Group reduced their price target on shares of Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a research note on Wednesday, March 11th. BTIG Research dropped their target price on shares of Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, March 5th. JPMorgan Chase & Co. set a $35.00 price target on Progyny in a research note on Wednesday, January 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a research note on Monday, December 29th. Finally, Citigroup raised Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and a consensus target price of $27.91.

Progyny Stock Down 0.3%

NASDAQ:PGNY opened at $18.13 on Friday. Progyny has a 52 week low of $16.75 and a 52 week high of $28.75. The stock’s fifty day moving average is $21.40 and its two-hundred day moving average is $22.54. The company has a market capitalization of $1.48 billion, a P/E ratio of 27.89, a P/E/G ratio of 1.05 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Sell-side analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the sale, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 7,455 shares of company stock worth $129,515 over the last 90 days. 9.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Progyny

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Progyny by 2.4% during the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after buying an additional 235,513 shares in the last quarter. State Street Corp lifted its stake in Progyny by 1.5% in the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock worth $75,838,000 after acquiring an additional 44,642 shares during the last quarter. Wellington Management Group LLP grew its holdings in Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after acquiring an additional 1,621,688 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Progyny by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock valued at $50,655,000 after purchasing an additional 20,533 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.